Abstracts S209 ized with acute comorbidities and offer treatment. This ur- ban, academic health center developed a population-level strategy to address this crisis across its inpatient units. The SUIT is a multidisciplinary consultation team, of addiction medicine specialists from emergency medicine,psychiatry, toxicology, social work, and pharmacology. This report sum- marizes and assesses the results from the first five months of SUIT’s implementation; preliminary findings indicate SUIT is associated with screening successes, identification and treatment of opioid misuse, and reduced length of stay and 30-day readmission. Objective: In 2017, an academic health center in Chicago launched the multidisciplinary Substance Use Intervention Team (SUIT) to address opioid misuse across 18 inpatient units and in a new outpatient addiction medicine clinic. This report assesses the first 5 months of implementation and associations with patient health and healthcare utilization. Methods: Patient demographic and screening data were ex- tracted from the administrative data warehouse of the elec- tronic health record (EHR) infrastructure. Distribution of sample characteristics for positive initial screens for opi- oid misuse was tested against those of all patients screened using a 2-tailed test of proportions (P<0.05). A second anal- ysis compared length of stay and 30-day readmissions within a cohort of patients with a secondary diagnosis of substance use disorder. Results: Between November, 2017 and March, 2018, 76% of 15,054 unique patients were screened, 578 had positive scores on the Alcohol Use Disorders Identification Test and Drug Abuse Screening Test, 131 had positive scores for opi- oid misuse, and 52 patients initiated medication treatment. Patients with a secondary diagnosis of substance use dis- order who received a SUIT consult (n.161), compared with those who did not (n.612), had a shorter average length of stay (5.91 vs 6.73 days) and lower 30-day readmission rate (13.6% vs 15.7%). Conclusion: Leveraging the EHR to conduct standardized screenings and treatment has helped identify an at-risk population—disproportionately younger, black, and male— and treat new cases of opioid and substance misuse. The intervention indicates trends toward a shortened length of stay, reduced 30-day readmissions, and has linked patients to outpatient care. Electronic health record infrastructure offers the capacity to intervene on the opioid crisis at the population level, identifying a range of substance misuse and opioid dependency across inpatient units of a large aca- demic health center in Chicago. Screening rates are high, and the universal mode helps mitigate biases in the identi- fication of a substance misusing population. Moreover, the timely medication treatments and subsequent warm hand- offs linking patients to additional supportive therapies help ensure continuity of care and improved health outcomes. Longitudinal and outcomes data will inform future direc- tions for opioid prevention practice and policy. Replication of SUIT may be warranted at comparable hospitals in the face of this epidemic. Disclosure statement: Dr. Pollack reports grants from the National Institute of Health, Jansenn Pharmaceuticals and Wounded Warrior Project. He served on advisory boards or provided consultation to Aptinyx, Atlas Venture, Brackett Global, Lundbeck and Palo Alto Health Services. He has eq- uity from Argus, Doyen Medical, Mensante Corp, Midnsite, and Targia Pharmaceuticals. He receives royalties from the SIGH-A and the SAFER interviews. doi: 10.1016/j.euroneuro.2019.09.314 P.286 Olfactory neuroepithelium cells derived from humans to study mental disorders M. Hidalgo Figueroa 1,2,3,* , A. Delgado-Sequera 1,2 , M.C. Durán-Ruiz 1,4 , V. Perez 3,5 , J.A. Mico 1,3,6 , C. Castro 1,7 , R. De la Torre 8 , P. Robledo 8 , E. Berrocoso 1,2,3 1 Biomedical Research and Innovation Institute of Cádiz, IN- iBICA, Cádiz, Spain 2 University of Cadiz, Department of Psychology, Cadiz, Spain 3 Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, Instituto de Salud Carlos III, Madrid, Spain 4 University of Cadiz, Biomedicine- Biotechnology and Pub- lic Health Department, Cadiz, Spain 5 Institut de Neuropsiquiatria i Addiccions- Hospital del Mar- IMIM Barcelona, Department of Psychiatry- Univ Au- tonoma de Barcelona, Barcelona, Spain 6 University of Cadiz, Department of Neuroscience, Cadiz, Spain 7 University of Cadiz, Department of Medicine- Area of Physiology, Cadiz, Spain 8 Integrative Pharmacology and Systems Neuroscience, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain Background: The study of mental disorders has been diffi- cult due to the impossibility to obtain brain biopsies from alive patients. In order to study neuronal function in peo- ple suffering from mental illness, recent studies describe the use of differentiated neurons derived from iPSC-derived fibroblasts from patients. Although this is an interesting cel- lular model, it has several limitations, including difficulty to reprogram these cells and the long time it requires. The ol- factory neuroepithelium (ON) contains a neurogenic niche that gives rise to olfactory sensory neurons throughout life. Neuronal progenitors from this tissue are easily extracted from humans and can be propagated and differentiated into neurons under appropriate in vitro conditions. These char- acteristics make the ON a useful cellular model to study mental disorders, especially those with a neurodevelopmen- tal origin, since alterations occurring during neural progeni- tor proliferation and differentiation can be studied in vitro. Patients suffering from schizophrenia (SZ) present alter- ations in neuronal morphology and function and may have a neurodevelopmental origin. Thus, cells from ON are useful to study those alterations. There is a link between cannabis use during adolescence and the early onset schizophrenia, in people with high vulnerability to develop this disease. Methods: We are using cells derived from the ON from cannabis users and healthy controls to study cellular alter- ations involved in this link. Our goals are 1) to better under- stand neuronal mechanisms altered in cannabis users and its relationship with schizophrenia development. 2) To look for biomarkers that could help to design new drugs to act